| |
| | MAGNUM Press Release May 1998 |
 | | Over-medication using Excedrin® Migraine, or other OTC pain medication, can, in turn, cause 'rebound headaches,' which, in turn, can lead to the taking of more OTC medication, the onset of more rebound headaches, and the re-triggering of even more serious Migraine attacks. |
 | | The FDA issued their statements on Excedrin® Migraine after taking into account three clinical studies which demonstrated the safety and effectiveness of Excedrin® Migraine for alleviating pain associated with some Migraines. |
 | | Although the studies may have demonstrated the effectiveness of the drug in alleviating pain associated with certain migraines that may be characterized by some as severe, the FDA chose to restrict their Excedrin® Migraine approval statements to the treatment of mild to moderate migraines. |
| www.migraines.org /new/news9805.htm (603 words) |
|